If You Invested in Centogene N.V. (CNTGF)

Centogene N.V. (CNTGF), commonly referred to as CENTOGENE, has historically operated in the diagnostics and research space within the healthcare sector, with a focus on rare and neurodegenerative diseases. According to company disclosures, CENTOGENE describes itself as an essential life science partner for data-driven answers in these disease areas, integrating multiomic technologies with its proprietary CENTOGENE Biodatabank to support precision medicine.

Founded in 2006, CENTOGENE states that it has built a network of approximately 30,000 active physicians and operates ISO, CAP, and CLIA certified multiomic reference laboratories in Germany. These laboratories work with Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. The company reports that data from over 850,000 patients from more than 120 highly diverse countries are captured in the CENTOGENE Biodatabank, with over 70% of patients of non-European descent. This dataset has contributed to generating insights for more than 300 peer-reviewed publications, according to the company.

CENTOGENE indicates that it has supported over 50 collaborations with pharmaceutical partners. In these collaborations, it reports activities in target and drug screening, clinical development, and market access and expansion, as well as providing CENTOGENE Biodata Licenses and Insight Reports. The company positions these activities as ways to accelerate and de-risk drug discovery, development, and commercialization in rare and neurodegenerative diseases.

Business focus and capabilities

Based on company descriptions, CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies. It states that it offers rapid and reliable diagnosis in rare and neurodegenerative diseases and that its multiomic approach enables dimensional analysis to guide precision medicine. The company emphasizes that its data and expertise are translated into tangible insights that support disease understanding, diagnosis, and drug development.

CENTOGENE has highlighted its work in Parkinson’s disease through the Rostock International Parkinson's Disease (ROPAD) Study, a global epidemiological study focusing on the role of genetics in Parkinson’s disease. The stated goal of ROPAD is to characterize the genetics of Parkinson’s disease to improve understanding of disease etiology, diagnosis, and severity. The company reports that over 18,000 participants from around the world have been tested over a multi-year period using its CentoCard® dried blood spot collection kit combined with sequencing technologies to screen for mutations in known Parkinson’s disease-associated genes.

In published data from ROPAD, CENTOGENE has reported findings on the RAB32 c.213C>G (p.Ser71Arg) variant as a genetic risk factor and potential monogenic cause of Parkinson’s disease. The company notes that this mutation was found in a subset of Parkinson’s patients at a prevalence substantially higher than in general population databases, supporting its relevance as a cause of disease. These results are presented by CENTOGENE as an example of how its genetic datasets and collaborations can generate insights that may inform research and potential treatment development.

CENTOGENE Biodatabank and multiomic approach

The CENTOGENE Biodatabank is described by the company as a central asset that aggregates multiomic and clinical data from a large and diverse patient population. By integrating Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic information, CENTOGENE states that it can perform dimensional analyses that support precision medicine in rare and neurodegenerative diseases. The company indicates that this resource underpins its diagnostic services, research collaborations, and pharma partnerships.

According to company materials, the Biodatabank’s diversity—both in terms of geography and ancestry—is a key feature, with patients represented from over 120 countries and a majority reported to be of non-European descent. CENTOGENE presents this diversity as important for uncovering genetic variants and disease patterns that might otherwise be underrepresented, and as a basis for its contributions to hundreds of peer-reviewed publications.

Corporate restructuring, liquidation, and trading status

Recent company announcements describe a significant change in CENTOGENE’s corporate structure and operations. On November 13, 2024, Centogene N.V. announced that it had entered into a Share Purchase Agreement to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited, a pan-European private equity firm. The transaction included the sale of 100% ownership in Centogene GmbH, described as CENTOGENE’s sole operating subsidiary, certain intercompany receivables, and the assumption of the company’s loan granted by Oxford Finance LLC.

On December 4, 2024, CENTOGENE reported that shareholders at an Extraordinary General Meeting voted in favor of all proposals, including approval of the envisaged sale and transfer of Centogene GmbH to Charme Capital Partners. On March 12, 2025, the company announced the closing of the transaction to sell its operating subsidiaries to an affiliate of Charme.

Following the closing of this transaction, Centogene N.V. stated that the company and its remaining subsidiary, Centogene Switzerland AG, will no longer have any operations. The company has indicated that it intends to liquidate Centogene Switzerland AG and that Centogene N.V. will enter dissolution and liquidation in accordance with the laws of the Netherlands and its organizational documents, as resolved upon by shareholders at the Extraordinary General Meeting. The company has also stated that its reporting obligations under the U.S. Securities Exchange Act have been suspended and that it expects its securities to cease to be quoted on the OTC market.

Company communications further state that it is expected there will be a liquidation distribution to shareholders, with the exact amount, record date, and payment date dependent on the outcome of the liquidation process, running costs, reserves, and applicable law. These details are described by the company as subject to the liquidation process and related factors.

Historical context for investors

For investors researching CNTGF, it is important to note that Centogene N.V. has communicated its intention to dissolve and liquidate following the sale of its operating subsidiaries, and that, according to the company, it will no longer have operating businesses. The historical business of CENTOGENE, as described in its own materials, centered on multiomic diagnostics, rare and neurodegenerative disease research, and collaborations with physicians and pharmaceutical partners supported by the CENTOGENE Biodatabank and associated laboratories.

Going forward, CNTGF primarily represents the residual corporate entity in liquidation rather than an operating diagnostics and research company. Historical information about CENTOGENE’s diagnostic services, research activities, and collaborations remains relevant for understanding the background of the business that was sold to Charme Capital Partners, while current and future developments for the underlying operations are expected to be associated with the acquiring entity and its affiliates.